US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Alumis Inc.

4.69

-0.3100-6.20%

Volume:163.64K

Turnover:779.29K

Market Cap:255.17M

PE:-0.45

High:5.03

Open:4.97

Low:4.65

Close:5.00

Loading ...

Overview Company News Filings

BRIEF-Alumis And Acelyrin Announce Amended Merger Agreement

Alumis Raises Share Consideration for Acelyrin Acquisition

MT Newswires Live

ACELYRIN, INC. Amends Merger Agreement with Alumis

Alumis Inc - Expects Runway to Fund Operations Into 2027

THOMSON REUTERS

Alumis and ACELYRIN Announce Amended Merger Agreement

THOMSON REUTERS

Alumis Inc - ACELYRIN Stockholders to Receive 0.4814 Shares of Alumis per Share

THOMSON REUTERS

Press Release: Alumis and ACELYRIN Announce Amended Merger Agreement

new option listings on April 9th

Alumis Down Over 31%, on Track for Record Percent Decrease -- Data Talk

Alumis Reaches US$465m Market Cap Benefiting Insider Stock Buying

Simply Wall St.

Alumis and ACELYRIN File Joint Definitive Proxy Statement for Proposed Merger

THOMSON REUTERS

Alumis Inc. Reports 2024 Results and Strategic Merger

Alumis Price Target Maintained With a $15.00/Share by HC Wainwright & Co.

Sector Update: Health Care Stocks Decline Tuesday Afternoon

MT Newswires Live

BUZZ-Alumis jumps on licensing deal for skin drug

Alumis Shares Rise on Licensing Agreement with Japanese Drug Company

Alumis Shares up 26.5% After Licensing Agreement With Kaken Pharmaceutical

THOMSON REUTERS

Alumis Shares Jump 67.4% Premarket After Licensing Agreement With Kaken Pharmaceutical

THOMSON REUTERS

Alumis, Kaken Pharmaceutical Enter Collaboration, Licensing Deal for Dermatology Drug

MT Newswires Live

BRIEF-Alumis And Kaken Pharmaceutical Announce Collaboration And Licensing Agreement For ESK-001 In Dermatology In Japan

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/ALMS/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ALMS","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ALMS\",,,,,undefined,":{"symbol":"ALMS","market":"US","secType":"STK","nameCN":"Alumis Inc.","latestPrice":4.69,"timestamp":1745263246173,"preClose":5,"halted":0,"volume":163636,"delay":0,"floatShares":4764683,"shares":54407327,"eps":-10.381567,"marketStatus":"Trading","change":-0.31,"latestTime":"04-21 15:21:31 EDT","open":4.97,"high":5.0306,"low":4.645,"amount":779289.4500600001,"amplitude":0.07712,"askPrice":4.72,"askSize":247,"bidPrice":4.67,"bidSize":456,"shortable":3,"etf":0,"ttmEps":-10.381567,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1745265600000},"marketStatusCode":2,"adr":0,"listingDate":1719547200000,"exchange":"NASDAQ","adjPreClose":5,"preHourTrading":{"tag":"盘前","latestPrice":5,"preClose":5,"latestTime":"09:27 EDT","volume":549,"amount":2750.7725703,"timestamp":1745242073480},"postHourTrading":{"tag":"盘后","latestPrice":4.94,"preClose":5,"latestTime":"17:27 EDT","volume":1826,"amount":9076.4,"timestamp":1744925268976},"volumeRatio":0.511245,"optionData":{"bulkOrders":[{"symbol":"ALMS","call":true,"expireDate":1752811200000,"strike":"5.0","timestamp":1745244107349,"price":0.45,"volume":5000,"amount":225000,"type":"-"}]},"impliedVol":0.7661,"impliedVolPercentile":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ALMS\",,,,,undefined,":{"symbol":"ALMS","floatShares":4764683,"roa":"-87.31%","roe":"-198.66%","lyrEps":-10.381567,"volumeRatio":0.511245,"shares":54407327,"dividePrice":0,"high":5.0306,"amplitude":0.07712,"preClose":5,"low":4.645,"week52Low":3.18,"pbRate":"0.98","week52High":13.53,"institutionHeld":0,"latestPrice":4.69,"committee":0.297297,"eps":-10.381567,"divideRate":0,"volume":163636,"delay":0,"ttmEps":-10.381567,"open":4.97,"prevYearClose":7.86,"prevWeekClose":5,"prevMonthClose":6.14,"prevQuarterClose":6.14,"fiveDayClose":6.48,"twentyDayClose":3.75,"sixtyDayClose":6.57},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ALMS\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2529870756","title":"BRIEF-Alumis And Acelyrin Announce Amended Merger Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2529870756","media":"Reuters","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529870756?lang=en_us&edition=fundamental","pubTime":"2025-04-21 19:53","pubTimestamp":1745236410,"startTime":"0","endTime":"0","summary":"BRIEF-Alumis And Acelyrin Announce Amended Merger AgreementApril 21 (Reuters) - Alumis Inc ALMS.O:ALUMIS AND ACELYRIN ANNOUNCE AMENDED MERGER AGREEMENTALUMIS INC - ACELYRIN STOCKHOLDERS TO RECEIVE 0.4","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250421:nTUA46YLXT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLRN","BK4139","ALMS","BK4007"],"gpt_icon":0},{"id":"2529141872","title":"Alumis Raises Share Consideration for Acelyrin Acquisition","url":"https://stock-news.laohu8.com/highlight/detail?id=2529141872","media":"MT Newswires Live","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529141872?lang=en_us&edition=fundamental","pubTime":"2025-04-21 19:17","pubTimestamp":1745234276,"startTime":"0","endTime":"0","summary":"Alumis (ALMS) and Acelyrin (SLRN) said Monday that they agreed on an amended merger deal that reflects an increased share consideration for each Acelyrin share.Under the amended agreement, Acelyrin sh","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ALMS","BK4139","SLRN","BK4007"],"gpt_icon":0},{"id":"2529874693","title":"ACELYRIN, INC. Amends Merger Agreement with Alumis","url":"https://stock-news.laohu8.com/highlight/detail?id=2529874693","media":"TIPRANKS","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529874693?lang=en_us&edition=fundamental","pubTime":"2025-04-21 18:57","pubTimestamp":1745233061,"startTime":"0","endTime":"0","summary":"ACELYRIN, INC. ( ($SLRN) ) just unveiled an announcement. On February 6, 2025, ACELYRIN, INC. entered into a merger agreement with Alumis Inc., whi...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/acelyrin-inc-amends-merger-agreement-with-alumis?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/acelyrin-inc-amends-merger-agreement-with-alumis?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ALMS","BK4139","SLRN","INC","BK4007"],"gpt_icon":0},{"id":"2529879143","title":"Alumis Inc - Expects Runway to Fund Operations Into 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2529879143","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529879143?lang=en_us&edition=fundamental","pubTime":"2025-04-21 18:30","pubTimestamp":1745231400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250421:nTUA46YLXT:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","SLRN","BK4139","ALMS"],"gpt_icon":0},{"id":"2529879642","title":"Alumis and ACELYRIN Announce Amended Merger Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2529879642","media":"THOMSON REUTERS","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529879642?lang=en_us&edition=fundamental","pubTime":"2025-04-21 18:30","pubTimestamp":1745231400,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250421:nTUAYZMWC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ALMS","SLRN","BK4007","BK4139"],"gpt_icon":0},{"id":"2529687950","title":"Alumis Inc - ACELYRIN Stockholders to Receive 0.4814 Shares of Alumis per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2529687950","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529687950?lang=en_us&edition=fundamental","pubTime":"2025-04-21 18:30","pubTimestamp":1745231400,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250421:nTUAYZMWC:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ALMS","BK4007","BK4139","SLRN"],"gpt_icon":0},{"id":"2529879600","title":"Press Release: Alumis and ACELYRIN Announce Amended Merger Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2529879600","media":"Dow Jones","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529879600?lang=en_us&edition=fundamental","pubTime":"2025-04-21 18:30","pubTimestamp":1745231400,"startTime":"0","endTime":"0","summary":"ACELYRIN stockholders to receive increased ownership in the combined company through revised exchange ratio; Alumis and ACELYRIN stockholders to now own approximately 52% and 48%, respectively, of the combined company on a fully diluted basis. Merger maximizes the potential value for ACELYRIN stockholders and creates a stronger combined company, best-positioned to realize long-term value of multiple late-stage assets. Bruce Cozadd, Chair of the ACELYRIN Board of Directors and member of the Board Transaction Committee, said, \"Since announcing the merger, we have had extensive conversations with our stockholders who have expressed an understanding of the strategic rationale for this transaction, while also sharing their perspectives on the","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ALMS"],"gpt_icon":0},{"id":"2526636636","title":"new option listings on April 9th","url":"https://stock-news.laohu8.com/highlight/detail?id=2526636636","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526636636?lang=en_us&edition=fundamental","pubTime":"2025-04-09 20:30","pubTimestamp":1744201816,"startTime":"0","endTime":"0","summary":"New option listings for April 9th include Alumis Inc (ALMS), LEVERAGE SHARES 2X LONG ASML DAILY ETF (ASMG), Arrivent Biopharma Inc (AVBP), REX BITC...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/new-option-listings-on-april-9th?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/new-option-listings-on-april-9th?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","LU0823434740.USD","AVBP","LU2063271972.USD","03165","BK4139","BK4543","LU0097036916.USD","BK4147","LU1734074674.USD","BK4007","LU0345774631.USD","LU0345774391.USD","LU0823434583.USD","ALMS","IE0004445239.USD","ASMG","FDN","BK4550","IE00BD6J9T35.USD","BK4588"],"gpt_icon":0},{"id":"2526842476","title":"Alumis Down Over 31%, on Track for Record Percent Decrease -- Data Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2526842476","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526842476?lang=en_us&edition=fundamental","pubTime":"2025-04-09 03:22","pubTimestamp":1744140120,"startTime":"0","endTime":"0","summary":"Alumis Inc.  is currently at $6.93, down $3.14 or 31.18%. --Would be lowest close since March 31, 2025, when it closed at $6.14. --Down 47.89% from its all-time closing high of $13.30 on June 28, 2024. --Up 94.12% from its 52-week closing low of $3.57 on March 20, 2025. --Down 33.57% at today's intraday low; largest intraday percent decrease on record ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ALMS"],"gpt_icon":0},{"id":"2525710867","title":"Alumis Reaches US$465m Market Cap Benefiting Insider Stock Buying","url":"https://stock-news.laohu8.com/highlight/detail?id=2525710867","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525710867?lang=en_us&edition=fundamental","pubTime":"2025-04-05 22:55","pubTimestamp":1743864920,"startTime":"0","endTime":"0","summary":"Insiders who bought Alumis Inc. ( NASDAQ:ALMS ) stock in the last 12 months were richly rewarded last week. The...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-alms/alumis/news/alumis-reaches-us465m-market-cap-benefiting-insider-stock-bu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ALMS","BK4007"],"gpt_icon":0},{"id":"2525980730","title":"Alumis and ACELYRIN File Joint Definitive Proxy Statement for Proposed Merger","url":"https://stock-news.laohu8.com/highlight/detail?id=2525980730","media":"THOMSON REUTERS","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525980730?lang=en_us&edition=fundamental","pubTime":"2025-04-05 04:34","pubTimestamp":1743798891,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250404:nTUA8HQXBC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SLRN","ALMS","BK4007","BK4139"],"gpt_icon":0},{"id":"2522390295","title":"Alumis Inc. Reports 2024 Results and Strategic Merger","url":"https://stock-news.laohu8.com/highlight/detail?id=2522390295","media":"TIPRANKS","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522390295?lang=en_us&edition=fundamental","pubTime":"2025-03-27 12:00","pubTimestamp":1743048049,"startTime":"0","endTime":"0","summary":"Alumis Inc. ( ($ALMS) ) has released its Q4 earnings. Here is a breakdown of the information Alumis Inc. presented to its investors. Alumis Inc. is...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/alumis-inc-reports-2024-results-and-strategic-merger?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/alumis-inc-reports-2024-results-and-strategic-merger?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ALMS","BK4007"],"gpt_icon":0},{"id":"2522820870","title":"Alumis Price Target Maintained With a $15.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2522820870","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522820870?lang=en_us&edition=fundamental","pubTime":"2025-03-26 18:54","pubTimestamp":1742986440,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ALMS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 26, 2025 06:54 ET (10:54 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALMS"],"gpt_icon":0},{"id":"2522885443","title":"Sector Update: Health Care Stocks Decline Tuesday Afternoon","url":"https://stock-news.laohu8.com/highlight/detail?id=2522885443","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522885443?lang=en_us&edition=fundamental","pubTime":"2025-03-26 01:56","pubTimestamp":1742925375,"startTime":"0","endTime":"0","summary":"Health care stocks were falling Tuesday afternoon, with the NYSE Health Care Index and the Health Care Select Sector SPDR Fund  each down about 1.1%.The iShares Biotechnology ETF  fell 1.4%.In corporate news, 23andMe's  customers were asked by New York Attorney General Letitia James to take action for protection of their data as the company goes through bankruptcy, the state prosecutor's office said in a consumer alert Tuesday. 23andMe shares were falling past 13%.Merck  secured exclusive global rights to develop and sell China-based Jiangsu Hengrui Pharmaceuticals' heart disease drug in a deal worth up to about $2 billion. Merck shares were down 4.1%.Alumis  shares rose past 7% after the company and Kaken Pharmaceutical said they signed a collaboration and licensing agreement to develop, manufacture, and commercialize ESK-001 for dermatology indications in Japan, with an option to expand the license to include rheumatological and gastrointestinal diseases.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0211331839.USD","ME","SG9999015358.SGD","LU1037948541.HKD","LU1983299246.USD","LU1917777945.USD","BK4588","SG9999014567.USD","LU1061106388.HKD","LU1116320737.USD","IE00BSNM7G36.USD","LU0320765489.SGD","LU0122379950.USD","LU0289739699.SGD","LU0203345920.USD","IE00B2B36J28.USD","LU2361044949.HKD","LU2112291526.USD","ALMS","LU1571399168.USD","LU0203347892.USD","LU2089984988.USD","IE00BN8TJ469.HKD","MEHCQ","LU1035773651.USD","MRK","LU1989771016.USD","LU1069347547.HKD","LU1941712264.USD","IE000M9KFDE8.USD","IBB","SG9999013999.USD","BK4534","LU2106854487.HKD","SG9999002232.USD","SG9999014542.SGD","LU0238689110.USD","BK4516","IE0002141913.USD","SG9999001176.USD","LU0985320562.USD","SG9999001176.SGD","LU0106261372.USD","LU1116320901.HKD","LU2468319806.SGD","LU1934455863.HKD","XLV","LU2023250843.SGD","LU0861579265.USD","LU1093756168.USD","LU1066051498.USD"],"gpt_icon":0},{"id":"2522009493","title":"BUZZ-Alumis jumps on licensing deal for skin drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2522009493","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522009493?lang=en_us&edition=fundamental","pubTime":"2025-03-25 23:25","pubTimestamp":1742916325,"startTime":"0","endTime":"0","summary":"BUZZ-Alumis jumps on licensing deal for skin drug** Shares of biopharmaceutical firm Alumis ALMS.O rise 15.5% to $4.36, hitting over one-month high** ALMS and Tokyo-based Kaken Pharmaceutical 4521.T say they have entered into a licensing agreement to develop, manufacture and commercialize an experimental skin drug in Japan** ALMS' lead drug candidate, ESK-001, is currently in a late-stage study which aims to fix immune system issues in various diseases caused by inflammatory substances like IL-23, IL-17, and type 1 interferon** ALMS will receive $40 million in upfront and near-term co-development payments in 2025 to 2026** The company could earn up to $140 million more based on milestone achievements** ESK-001 is also being tested in a mid-stage study to treat a type of autoimmune disease called systemic lupus erythematosus** ALMS has fallen 44.4% YTD  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250325:nL6N3Q80KT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ALMS"],"gpt_icon":0},{"id":"2522006287","title":"Alumis Shares Rise on Licensing Agreement with Japanese Drug Company","url":"https://stock-news.laohu8.com/highlight/detail?id=2522006287","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522006287?lang=en_us&edition=fundamental","pubTime":"2025-03-25 23:12","pubTimestamp":1742915520,"startTime":"0","endTime":"0","summary":"Alumis shares rose after the company signed a licensing agreement, worth $40 million in the short-term, with Tokyo-based Kaken Pharmaceutical.The stock climbed 17.9% to $4.45 on Tuesday, recovering some of the loss over the past few days that brought the stock to a 52-week low on Friday. Shares are down 43% this year.The San Francisco biotechnology company said Tuesday it entered a collaboration and licensing agreement to develop, manufacture and commercialize ESK-001, an oral tyrosine kinase 2 inhibitor.The treatment is designed for dermatology use in Japan, but could be expanded to include rheumatological and gastrointestinal diseases. It uses proinflammatory mediators to correct immune dysregulation across several diseases.Alumis is set to receive $40 million for immediate co-development payments in 2025 and 2026. It has the potential to earn up to $140 million in additional payments based on field option payments and reaching milestones.Alumis is also eligible to receive tiered roy","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Alumis Shares Rise on Licensing Agreement with Japanese Drug Company","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALMS","BK4007"],"gpt_icon":0},{"id":"2522074761","title":"Alumis Shares up 26.5% After Licensing Agreement With Kaken Pharmaceutical","url":"https://stock-news.laohu8.com/highlight/detail?id=2522074761","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522074761?lang=en_us&edition=fundamental","pubTime":"2025-03-25 21:34","pubTimestamp":1742909677,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250325:nFWN3Q81EL:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ALMS","BK4007"],"gpt_icon":0},{"id":"2522075351","title":"Alumis Shares Jump 67.4% Premarket After Licensing Agreement With Kaken Pharmaceutical","url":"https://stock-news.laohu8.com/highlight/detail?id=2522075351","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522075351?lang=en_us&edition=fundamental","pubTime":"2025-03-25 20:46","pubTimestamp":1742906791,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250325:nL3N3Q80V5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ALMS"],"gpt_icon":0},{"id":"2522209730","title":"Alumis, Kaken Pharmaceutical Enter Collaboration, Licensing Deal for Dermatology Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2522209730","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522209730?lang=en_us&edition=fundamental","pubTime":"2025-03-25 16:28","pubTimestamp":1742891285,"startTime":"0","endTime":"0","summary":"Alumis  and Kaken Pharmaceutical have struck a collaboration and licensing agreement to develop, manufacture and commercialize ESK-001 for dermatology indications in Japan, with an option to expand the license to include rheumatological and gastrointestinal diseases, the companies said Tuesday.Under the terms of the agreement, Alumis will receive $40 million in upfront and near-term co-development payments this year and next year, with the potential to earn up to approximately $140 million in additional milestone payments, the companies said.Alumis is also eligible to receive tiered royalties ranging from the low double-digits into the twenties on total Japanese net sales of ESK-001, the companies said.Kaken will be responsible for the clinical development, regulatory approvals and commercialization of ESK-001 in Japan and contribute toward global development costs of the drug, the companies said.The drug is currently being evaluated in a phase 3 clinical trial for patients with modera","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","ALMS"],"gpt_icon":0},{"id":"2522091486","title":"BRIEF-Alumis And Kaken Pharmaceutical Announce Collaboration And Licensing Agreement For ESK-001 In Dermatology In Japan","url":"https://stock-news.laohu8.com/highlight/detail?id=2522091486","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522091486?lang=en_us&edition=fundamental","pubTime":"2025-03-25 16:03","pubTimestamp":1742889810,"startTime":"0","endTime":"0","summary":"BRIEF-Alumis And Kaken Pharmaceutical Announce Collaboration And Licensing Agreement For ESK-001 In Dermatology In JapanMarch 25 (Reuters) - Alumis Inc ALMS.O:ALUMIS AND KAKEN PHARMACEUTICAL ANNOUNCE ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250325:nTUABZHV5J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ALMS"],"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":1,"totalSize":98,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ALMS\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-03-19","symbol":"ALMS","fiscalQuarterEnding":"2024/12","expectedEps":-1.39,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1742356800000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2024-11-13","symbol":"ALMS","fiscalQuarterEnding":"2024/09","expectedEps":-1.64,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1731474000000,"reportTimeType":"post","actualEps":-1.73}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ALMS\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ALMS\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.6,"buy":0.4,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.6,"analysts":5,"updateTime":1738296000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ALMS\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ALMS","date":"2025-04-17","current":-0.937506,"percent":0.962567,"low":-5.220865,"twenty":-3.463917,"median":-2.033661,"eighty":-1.195689,"high":-0.660137,"avg":-2.395677,"sd":1.056359,"marketCap":275845147},"quantilePoints":[{"date":"2024-06-28","current":-5.220865,"twenty":-5.220865,"median":-5.220865,"eighty":-5.220865,"marketCap":881360393},{"date":"2024-07-05","current":-3.577828,"twenty":-4.31182,"median":-3.851156,"eighty":-3.577828,"marketCap":603991092},{"date":"2024-07-12","current":-3.798947,"twenty":-4.001025,"median":-3.825051,"eighty":-3.577828,"marketCap":641319297},{"date":"2024-07-15","current":-3.405847,"twenty":-3.980142,"median":-3.798947,"eighty":-3.577828,"marketCap":574958044},{"date":"2024-08-02","current":-4.08515,"twenty":-4.063676,"median":-3.825051,"eighty":-3.577828,"marketCap":689634611},{"date":"2024-08-09","current":-3.930629,"twenty":-4.063676,"median":-3.914533,"eighty":-3.58397,"marketCap":663549141},{"date":"2024-08-16","current":-3.699952,"twenty":-4.025518,"median":-3.855481,"eighty":-3.617622,"marketCap":699416662},{"date":"2024-08-23","current":-3.709695,"twenty":-3.973459,"median":-3.817957,"eighty":-3.659922,"marketCap":701258562},{"date":"2024-08-30","current":-3.67516,"twenty":-3.943506,"median":-3.741353,"eighty":-3.65762,"marketCap":694730166},{"date":"2024-09-06","current":-3.390241,"twenty":-3.930629,"median":-3.739914,"eighty":-3.608539,"marketCap":640870897},{"date":"2024-09-13","current":-3.240587,"twenty":-3.915649,"median":-3.699952,"eighty":-3.511116,"marketCap":612581180},{"date":"2024-09-20","current":-3.272245,"twenty":-3.914533,"median":-3.679477,"eighty":-3.395997,"marketCap":618565543},{"date":"2024-09-27","current":-3.444923,"twenty":-3.859807,"median":-3.655014,"eighty":-3.33556,"marketCap":651207524},{"date":"2024-10-04","current":-2.886598,"twenty":-3.851156,"median":-3.617387,"eighty":-3.295269,"marketCap":545665119},{"date":"2024-10-11","current":-2.961425,"twenty":-3.850149,"median":-3.577828,"eighty":-3.211808,"marketCap":559809977},{"date":"2024-10-18","current":-3.200296,"twenty":-3.817957,"median":-3.47802,"eighty":-3.18015,"marketCap":604964718},{"date":"2024-10-25","current":-3.444923,"twenty":-3.798947,"median":-3.465068,"eighty":-3.200296,"marketCap":651207524},{"date":"2024-10-31","current":-3.231953,"twenty":-3.752872,"median":-3.462191,"eighty":-3.209506,"marketCap":610949081},{"date":"2024-11-08","current":-3.367218,"twenty":-3.741353,"median":-3.447801,"eighty":-3.218715,"marketCap":636518633},{"date":"2024-11-15","current":-2.144174,"twenty":-3.741353,"median":-3.444923,"eighty":-3.209506,"marketCap":511972947},{"date":"2024-11-22","current":-2.15101,"twenty":-3.739051,"median":-3.433411,"eighty":-3.073089,"marketCap":513605166},{"date":"2024-11-29","current":-2.109995,"twenty":-3.736748,"median":-3.419021,"eighty":-3.008623,"marketCap":503811848},{"date":"2024-12-06","current":-1.964163,"twenty":-3.720056,"median":-3.405847,"eighty":-2.970059,"marketCap":468991158},{"date":"2024-12-13","current":-1.989228,"twenty":-3.703849,"median":-3.378729,"eighty":-2.667081,"marketCap":474975964},{"date":"2024-12-20","current":-1.966442,"twenty":-3.691984,"median":-3.312536,"eighty":-2.153744,"marketCap":469535232},{"date":"2024-12-27","current":-1.916313,"twenty":-3.685521,"median":-3.301025,"eighty":-2.142807,"marketCap":457565620},{"date":"2025-01-03","current":-1.873019,"twenty":-3.682067,"median":-3.286635,"eighty":-2.0626,"marketCap":447228227},{"date":"2025-01-10","current":-1.752253,"twenty":-3.67516,"median":-3.266489,"eighty":-2.0029,"marketCap":418392344},{"date":"2025-01-17","current":-1.775039,"twenty":-3.672282,"median":-3.247782,"eighty":-1.966442,"marketCap":423833077},{"date":"2025-01-24","current":-1.497048,"twenty":-3.658468,"median":-3.227637,"eighty":-1.954138,"marketCap":357456138},{"date":"2025-01-31","current":-1.531227,"twenty":-3.654166,"median":-3.211808,"eighty":-1.919959,"marketCap":365617237},{"date":"2025-02-07","current":-1.501605,"twenty":-3.631778,"median":-3.162882,"eighty":-1.882133,"marketCap":358544284},{"date":"2025-02-14","current":-1.162092,"twenty":-3.62163,"median":-3.070787,"eighty":-1.832004,"marketCap":277477367},{"date":"2025-02-21","current":-1.168928,"twenty":-3.613315,"median":-3.018984,"eighty":-1.784609,"marketCap":279109587},{"date":"2025-02-28","current":-1.064112,"twenty":-3.590112,"median":-2.978693,"eighty":-1.743594,"marketCap":254082217},{"date":"2025-03-07","current":-1.162092,"twenty":-3.577828,"median":-2.970059,"eighty":-1.696654,"marketCap":277477367},{"date":"2025-03-14","current":-1.045883,"twenty":-3.561975,"median":-2.844868,"eighty":-1.612801,"marketCap":249729630},{"date":"2025-03-21","current":-0.660137,"twenty":-3.530406,"median":-2.358363,"eighty":-1.527581,"marketCap":194234157},{"date":"2025-03-28","current":-0.869088,"twenty":-3.513232,"median":-2.153288,"eighty":-1.493402,"marketCap":255714436},{"date":"2025-04-04","current":-1.579152,"twenty":-3.504209,"median":-2.144174,"eighty":-1.320049,"marketCap":464638572},{"date":"2025-04-11","current":-1.262952,"twenty":-3.478882,"median":-2.109995,"eighty":-1.320049,"marketCap":371602043},{"date":"2025-04-17","current":-0.937506,"twenty":-3.463917,"median":-2.033661,"eighty":-1.195689,"marketCap":275845147}],"updateTime":1745263291457}}}